VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Improving outcomes in KRAS-mutant pancreatic cancer

John H. Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the use of sotorasib and KRAS inhibitors in pancreatic cancer, as well as potential combinations to improve outcomes in KRAS-mutant patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter